(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 7.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Catalyst Pharmaceuticals's revenue in 2025 is $558,499,000.On average, 4 Wall Street analysts forecast CPRX's revenue for 2025 to be $68,666,864,205, with the lowest CPRX revenue forecast at $68,390,872,478, and the highest CPRX revenue forecast at $68,858,406,136. On average, 4 Wall Street analysts forecast CPRX's revenue for 2026 to be $76,409,319,498, with the lowest CPRX revenue forecast at $74,536,125,090, and the highest CPRX revenue forecast at $78,048,747,077.
In 2027, CPRX is forecast to generate $86,318,707,623 in revenue, with the lowest revenue forecast at $82,239,415,259 and the highest revenue forecast at $88,509,506,702.